Evaxion (NASDAQ: EVAX) to unveil new preclinical data on CMV vaccine EVX-V1

Rhea-AI Filing Summary

Evaxion A/S reports it will present new preclinical data for its cytomegalovirus (CMV) vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal. The poster on July 12, 2026 will highlight AI-driven multi-antigen vaccine design to address CMV infection, latency and immune evasion.

EVX-V1 combines novel AI-discovered CMV antigens with AI-optimized versions of established antigens, aiming for a broadly protective, multi-targeted vaccine approach. The new data are intended to guide final antigen selection as the program progresses. The filing also describes CMV’s high global prevalence and significant unmet medical need.

Key Figures

CMV treatment market size: $474.6 million CMV market CAGR: 6.6% annual growth Congenital CMV birth prevalence: 1 in 200 babies +3 more

6 metrics

CMV treatment market size $474.6 million Market size in 2023 for CMV treatment

CMV market CAGR 6.6% annual growth Projected CAGR between 2024 and 2032

Congenital CMV birth prevalence 1 in 200 babies Babies born with congenital CMV infection

Severe outcomes in congenital CMV 1 in 5 babies Infected babies with disabilities or long-term health problems

CMV adult infection prevalence 60%–70% / nearly 100% Adults infected in developed vs developing economies

Poster session date/time July 12, 2026, 9:30–11:30am ET EVX-V1 poster at International Herpesvirus Workshop 2026

Key Terms

AI-Immunology™, cytomegalovirus (CMV), pre-fusion glycoprotein B (gB), congenital CMV infection, +1 more

5 terms

AI-Immunology™ technical

"a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

cytomegalovirus (CMV) medical

"EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate"

pre-fusion glycoprotein B (gB) medical

"our proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen which has demonstrated superior performance"

congenital CMV infection medical

"About 1 in 200 babies is born with congenital CMV infection."

forward-looking statements regulatory

"This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/01/2026 - 08:05 AM Accepted by SEC EDGAR 07/01/2026 - 08:05 AM Learn about SEC filing dates

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On July 1, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit Number	Description
99.1	Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: July 1, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop

• New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine candidate
• Poster presentation on July 12, 2026, at the International Herpesvirus Workshop 2026 taking place in Montreal, Canada

COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present new preclinical data for vaccine candidate EVX-V1 in a poster session at the International Herpesvirus Workshop (IHW) 2026 taking place in Montreal, Canada, July 11-15, 2026.

EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.

The new preclinical data will guide final antigen selection for a broadly protective CMV vaccine candidate as we progress the program according to plan.

Presentations details:
Abstract title: AI-driven multi-antigen vaccine design to address cytomegalovirus infection, latency, and immune evasion
Poster#: P2.63
Session: Poster session 01
Location: Mont-Royal I/II, Centre Mont-Royal
Date/Time: July 12, 2026, at 9:30-11:30am ET/15:30-17:30 CET                 
Presenter: Gry Persson, Senior Project Manager at Evaxion

About EVX-V1
EVX-V1 is a next-generation, multi-component cytomegalovirus (CMV) vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. Through this combination, EVX-V1 attacks the virus from multiple, complementary angles. This broader multi-targeted strategy is expected to strengthen the protective potential of the vaccine.

With our AI-Immunology™ platform, we have uncovered novel antigens that are entirely new to the CMV vaccine research field. These previously unexplored CMV-antigens induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal viral infection models.

EVX-V1 is a combination of these antigens with our proprietary AI-optimized pre-fusion glycoprotein B (gB) antigen which has demonstrated superior performance compared to the traditional gB antigen, including enhanced CMV neutralization.

About CMV
About 1 in 200 babies is born with congenital CMV infection. About 1 in 5 babies with the infection will have congenital disabilities or other long-term health problems. CMV infects approximately 60% to 70% of adults in developed countries and nearly 100% in developing economies, driving demand for CMV treatment. Despite decades of research, no CMV vaccine has been approved to date.

CMV treatment market size was valued at $474.6 million in 2023 and is anticipated to register an annual growth (CAGR) of 6.6% between 2024 and 2032. This growth is propelled by increasing awareness and prevalence of CMV infection and the development of new and effective treatments.

CMV is the most complex of all herpes viruses and is a widespread infection transmitted in body fluids. Once infected, the virus stays for life. People with weakened immune systems, including organ transplant patients, can develop severe symptoms affecting, for example, eyes, lungs, and liver, and congenitally infected babies may suffer from intellectual disability and loss of vision and hearing.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What did Evaxion A/S (EVAX) announce about its CMV vaccine EVX-V1?

Evaxion A/S announced it will present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal. The data are intended to guide final antigen selection for a broadly protective, multi-component CMV vaccine candidate.

When and where will Evaxion present EVX-V1 preclinical data?

Evaxion will present EVX-V1 preclinical data on July 12, 2026, during Poster Session 01 at the International Herpesvirus Workshop in Montreal, Canada. The session runs from 9:30-11:30am ET (15:30-17:30 CET) at Centre Mont-Royal, room Mont-Royal I/II.

What is unique about Evaxion’s EVX-V1 CMV vaccine design?

EVX-V1 is described as a next-generation, multi-component CMV vaccine candidate combining novel AI-discovered antigens with AI-optimized versions of established CMV antigens. This multi-targeted approach aims to attack CMV from multiple complementary angles to strengthen the vaccine’s protective potential.

How does Evaxion’s AI-Immunology platform support EVX-V1?

Evaxion’s AI-Immunology platform is said to uncover novel CMV antigens and optimize existing ones, enabling rapid target discovery and vaccine design. For EVX-V1, the platform identified previously unexplored antigens that induce immune responses, inhibit infection and reduce cell-to-cell spread in model systems.

What medical need is Evaxion targeting with its CMV vaccine EVX-V1?

The company highlights that about 1 in 200 babies is born with congenital CMV infection and about 1 in 5 affected babies develops disabilities or long-term problems. CMV infects 60–70% of adults in developed countries and nearly 100% in developing economies, with no approved CMV vaccine to date.

How large is the CMV treatment market cited by Evaxion A/S (EVAX)?

Evaxion cites an estimated CMV treatment market size of $474.6 million in 2023, with a projected compound annual growth rate of 6.6% between 2024 and 2032. The company attributes this growth to rising CMV awareness, prevalence, and development of new treatment options.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 7.9 KB